首页> 外文学位 >Factors associated with adherence in heart failure. A secondary analysis of a large clinical trial: Candesartan in Heart failure -Assessment of Reduction in Mortality and Morbidity (CHARM)

【24h】

Factors associated with adherence in heart failure. A secondary analysis of a large clinical trial: Candesartan in Heart failure -Assessment of Reduction in Mortality and Morbidity (CHARM)

机译：与心力衰竭依从性相关的因素。大型临床试验的次要分析：坎地沙坦治疗心力衰竭-死亡率和发病率降低的评估（CHARM）

获取原文

获取原文并翻译 | 示例

页面导航

著录项
相似文献
相关主题

著录项

作者
Granger, Bradi B.;
展开▼
作者单位

The University of North Carolina at Chapel Hill;

展开▼
授予单位 The University of North Carolina at Chapel Hill;
学科
学位 Ph.D.
年度 2004
页码 134 p.
总页数 134
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. [J] . Omeara E, Lewis E, Granger C, European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology . 2005,第4期

机译：病人对坎地沙坦治疗心力衰竭的效果的认识。坎地沙坦心力衰竭的结果：死亡率和发病率降低计划的评估。
2. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial [J] . R.A.P. Weirab John J.V. McMurrayab* Margareta Puuc Scott D. Solomond Bertil Olofssonc Christopher B. Grangere Salim Yusuff Eric L. Michelsong Karl Swedbergh Marc A. Pfefferd and CHARM Investigators European Journal of Heart Failure . 2008,第2期

机译：在已经接受血管紧张素转换抑制剂加醛固酮拮抗剂（有或没有β受体阻滞剂）的心力衰竭患者中添加血管紧张素受体阻滞剂的疗效和耐受性。坎地沙坦在心力衰竭中的发现：死亡率和发病率降低的评估（CHARM）-添加的试验
3. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme [J] . Badar Athar A., Perez-Moreno Ana C., Hawkins Nathaniel M., European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology . 2015,第2期

机译：CHARM（坎地沙坦治疗心衰评估死亡率和发病率）计划中患有心绞痛和心力衰竭的患者的临床特征和预后
4. Trends in morbidity, mortality, and risk factorlevels of coronary heart disease in Japan-AreJapanese living in Japan still protected againstcoronary heart disease? [C] . Kazunori Kodam, Fumiyoshi Kasagi International Symposium on Atherosclerosis . 2004

机译：日本冠心病的发病率，死亡率和风险因子的趋势 - 居住在日本的依旧仍然保护患者患有急性心脏病症状？
5. Factors influencing adherence to a prescribed health regimen for individuals with heart failure. [D] . Scotto, Carol J. 2003

机译：影响心力衰竭患者遵守处方健康方案的因素。
6. Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program [O] . David Preiss, Sofia Zetterstrand, John J.V. McMurray, 2009

机译：坎地沙坦对心衰患者的死亡率和发病率降低（CHARM）程序进行评估时预测坎地沙坦对慢性心力衰竭患者糖尿病的发展趋势
7. Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme [O] . Eileen OMeara, Eldrin Lewis, Chris Granger, 2005

机译：患者对心力衰竭坎德坦治疗效果的看法。心力衰竭坎德坦的结果：降低死亡率和发病率降低（魅力）计划的评估
8. Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11; Heart Failure: Management of Patients with Left-Ventricular Systolic Dysfunction. Quick Reference Guide for Clinicians No. 11; Living with Heart Disease: Is It Heart Failure. Patient and Family Guide [R] . 1994

机译：心力衰竭：左心室收缩功能障碍患者的评估和护理。临床实践指南第11号;心力衰竭：左心室收缩功能障碍患者的治疗。临床医生快速参考指南第11号;与心脏病共存：是心衰吗？患者和家庭指南

Factors associated with adherence in heart failure. A secondary analysis of a large clinical trial: Candesartan in Heart failure -Assessment of Reduction in Mortality and Morbidity (CHARM)

著录项

相似文献

相关主题

期刊订阅